Impact of fluconazole administration on outcomes in critically ill patients

被引:5
|
作者
Garrelts, JC
Schroeder, TR
Harrison, PB
机构
[1] Wesley Med Ctr, Clin Pharm Serv & Res, Wichita, KS 67214 USA
[2] Wesley Med Ctr, Infect Dis, Wichita, KS 67214 USA
[3] Wesley Med Ctr, Trauma Program, Wichita, KS 67214 USA
关键词
fluconazole; outcomes; trauma;
D O I
10.1345/aph.1D441
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Serious infections caused by Candida spp. are an increasingly important cause of morbidity and mortality in critically ill patients. it is unclear which patients will benefit from therapy and at what point to institute treatment. OBJECTIVE: To evaluate the impact of administration of fluconazole therapy in critically ill trauma patients on mortality, length of hospital stay, incidence of deep-seated fungal infection, and positive fungal cultures from any site. METHODS: We conducted a retrospective, matched case-control study of 116 critically ill surgical trauma patients who did or did not receive fluconazole. Patients were followed until hospital discharge or death. A consecutive sample of 58 patients who received fluconazole was selected. A parallel group of patients was evaluated, from which 58 were matched with fluconazole-treated patients based on age (+/-5 y), gender, and APACHE II score (+/- 3). RESULTS: The groups of patients were well matched, with the exception of central venous catheter placement and broad-spectrum antibiotic use. We found no difference between groups in hospital mortality (21% vs 26%; p = 0.661) or incidence of deep-seated fungal infection (0% vs 2%; p = NS). However, patients receiving fluconazole had a significantly longer stay in both the intensive care unit (ICU) (18 +/- 13 vs 7 +/- 11 days; p < 0.001) and hospital (25 +/- 15 vs 9 +/- 11 days; p < 0.001). Fluconazole patients were significantly more likely to have Candida cultured from sites associated with colonization (43% vs 2%; p < 0.001), possibly explaining why they received fluconazole. CONCLUSIONS: We were unable to detect a benefit from use of fluconazole in our surgical trauma patient population. Isolation of Candida from the mouth or throat alone, in the absence of correlating clinical signs of infection, should not lead to initiation of fluconazole therapy. Fluconazole use should be reserved for carefully selected patients in the trauma ICU setting.
引用
收藏
页码:1588 / 1592
页数:5
相关论文
共 50 条
  • [1] Population pharmacokinetics of fluconazole after administration of fosfluconazole and fluconazole in critically ill patients
    Aoyama, T.
    Hirata, K.
    Hirata, R.
    Yamazaki, H.
    Yamamoto, Y.
    Hayashi, H.
    Matsumoto, Y.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (03) : 356 - 363
  • [2] Effects of fluconazole administration in critically ill patients - Analysis of bacterial and fungal resistance
    Rocco, TR
    Reinert, SE
    Simms, HH
    ARCHIVES OF SURGERY, 2000, 135 (02) : 160 - 165
  • [3] Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients
    Magill, SS
    Puthanakit, T
    Swoboda, SM
    Carson, KA
    Salvatori, R
    Lipsett, PA
    Hendrix, CW
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (07) : 2471 - 2476
  • [4] Pharmacokinetic evaluation of fluconazole in critically ill patients
    Sinnollareddy, Mahipal
    Peake, Sandra L.
    Roberts, Michael S.
    Playford, E. Geoffrey
    Lipman, Jeffrey
    Roberts, Jason A.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (11) : 1431 - 1440
  • [5] Impact of a Neurointensivist on Outcomes in Critically Ill Stroke Patients
    Knopf, Lisa
    Staff, Ilene
    Gomes, Joao
    McCullough, Louise
    NEUROCRITICAL CARE, 2012, 16 (01) : 63 - 71
  • [6] Impact of Contrast Echocardiography on Outcomes in Critically Ill Patients
    Main, Michael L.
    Fu, Julia Weleski
    Gundrum, Jake
    LaPointe, Nancy Allen
    Gillam, Linda D.
    Mulvagh, Sharon L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2021, 150 : 117 - 122
  • [7] Impact of a Neurointensivist on Outcomes in Critically Ill Stroke Patients
    Lisa Knopf
    Ilene Staff
    Joao Gomes
    Louise McCullough
    Neurocritical Care, 2012, 16 : 63 - 71
  • [8] RIFAMPIN-FLUCONAZOLE INTERACTION IN CRITICALLY ILL PATIENTS
    NICOLAU, DP
    CROWE, HM
    NIGHTINGALE, CH
    QUINTILIANI, R
    ANNALS OF PHARMACOTHERAPY, 1995, 29 (10) : 994 - 996
  • [9] Fluconazole prophylaxis in critically ill surgical patients: A metaanalysis
    Shorr, Andrew F.
    Chung, Kevin
    Jackson, William L.
    Waterman, Paige E.
    Kollef, Marin H.
    CRITICAL CARE MEDICINE, 2005, 33 (09) : 1928 - 1935
  • [10] Anidulafungin compared with fluconazole therapy in critically ill patients
    DH Kett
    AF Shorr
    AC Reboli
    AC Reisman
    P Biswas
    HT Schlamm
    Critical Care, 14 (Suppl 1):